Brain cell injection trial hopes to ease Parkinson's symptoms

NCT ID NCT07102342

Recruiting now Disease control Sponsor: iRegene Therapeutics Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new treatment called NouvNeu001 for people with advanced Parkinson's disease. It involves injecting special brain cells directly into areas of the brain that control movement. The study will enroll just 5 participants to see if the procedure is safe and tolerable, and to get a first look at whether it might improve motor and non-motor symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Human Dopaminergic Progenitor Cells (NouvNeu001)
What this could lead to: If it works, this could point toward a new way to replace lost brain cells and improve motor function in advanced Parkinson's disease.
What could go wrong: This is a very early, tiny trial with only 5 people. It is designed mainly to check safety, not prove effectiveness. Brain injections carry risks like bleeding or infection, and benefits may be minimal or absent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Locations

Cornell University Weill Medical College
RECRUITING

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.